- Blood (reviewer)
- Oncogene (reviewer)
- Expert Opinion On Therapeutic Targets (reviewer)
- Pharmacological Research (reviewer)
- Italian Ministry of Health (grant reviewer)
- Fondazione di Padova e Rovigo (grant reviewer)
I grew up in a small village of 3,000 inhabitants on the shore of Lago Maggiore in Italy. I attended medical school at Universita' Vita - Salute San Raffaele in Milan. For my graduation thesis, I worked under the supervision of Dr. Paolo Ghia and Dr. Caligaris-Cappio on Monoclonal B cell lymphocytosis. I was co-author of two publications in blood and cytometry B clin cytometry. After graduating in 2009, I moved to Boston, thanks to a fellowship grant from Cariplo Foundation, and started working as a post-doctoral fellow in the laboratory of Dr. Kenneth Anderson, a world-known expert of multiple myeloma and future president of the American Society of Hematology.Under his supervision, I published two first author publications and co-authored several other manuscripts. Specifically, one manuscript was published in 2014 in Nature Medicine, showing that YAP1, a transcriptional regulator of the Hippo pathway, is an essential factor in the control of apoptosis upon DNA damage in multiple myeloma and in other hematological malignancies. Re-activation of YAP1 by serine-threonin 4 (STK4) inhibition causes growth inhibition and apoptosis in hematological malignancies. These discoveries were highlighted in Nature Medicine, Cancer Discovery and Molecular and Cellular Oncology and endorsed in a U.S. patent. Specific STK4 inhibitors are under development thanks to collaborative LLS grant and to a personal IMF fellowship. Another original work has just been published in Cancer Discovery, demonstrating that replicative stress, a condition associated with incomplete or aberrant DNA synthesis at the level of fork replications, is present in multiple myeloma and causes together with oxidative stress ongoing DNA damage in a subset of patients with poor prognosis. Strategies coupling inhibition of DNA repair and induction of oxidative stress to trigger DNA damage represent a potent synthetic lethality approach in this cohort of patients with otherwise unfavorable outcomes.
Certifications and licensures:
Temporary Ohio Medical Board license
ACLS - BLS
Education:Internal Medicine Resident (Physician Scientist Track Program), The Ohio State University, 2015 - present
“Synthetic lethal approaches to exploit replicative stress in aggressive Myeloma”. 56th American Society of Hematology Annual meeting and Exposition, San Francisco, Session: 651. Myeloma - Biology and Pathophysiology, excluding Therapy: Mechanisms of Drug Resistance and Genomic Instability in Myeloma. Session Date and Time: Sunday, December 7, 2014: 5:30 p.m.
“Serine/Threonine kinase STK4 is a novel target in Myeloma” 56th American Society of Hematology Annual meeting and Exposition, San Francisco. Session Name: 652 Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Signal Transduction in Myeloma Monday, December 8, 2014: 5 p.m.
“Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma” AACR Special Conference: Hematologic Malignancies: Translating Discoveries to Novel Therapies, Philadelphia. Concurrent Session 2: Myeloma. Session Date and Time: Monday, September 22, 2014 from 10:30 a.m. - 12:30 p.m.
“Inhibition of the STK4 kinase restores the Hippo co-factor YAP1 and induces DNA- Francesca Cottini, MD damage mediated apoptosis in multiple myeloma cells” 10th Annual Postdoc and Graduate Student Dana-Farber Cancer Institute; Boston, MA. Session time: Thursday, September 18, 2014 from 1.30 p.m.
Inhibition of the STK4 kinase restores the hippo co-factor YAP1 and induces DNAdamage mediated apoptosis in multiple myeloma cells” 19th Congress of the European Hematology Association, Milan, Session: Myeloma and other monoclonal gammopathies – Biology; Date of presentation: Saturday, June 14 2014: 4:45 p.m.
The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma” International Myeloma Foundation (IMF) webcast interview selected, ASH meeting 2013, New Orleans
A novel target to treat hematopoietic malignancies” Italian Scientists and Scholars of North America Foundation Annual Meeting, Paola Campese Award, Italian Embassy in Washington, DC October 29th 2013
The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma”54th American Society of Hematology Annual meeting and Exposition, Atlanta, Session: 651. Myeloma - Biology and Pathophysiology, excluding Therapy: New Insights into Myeloma Biology from Clonogenic Cells to Circulating Tumor Cells Monday, December 10, 2012: 5:30 p.m.
Francesca Cottini, Teru Hideshima, Giovanni Tonon, and Kenneth Anderson (2015). “Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma” (American Society of Hematology meeting, 2015, Orlando)
Francesca Cottini, Teru Hideshima, Giovanni Tonon, and Kenneth Anderson (2014). “Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma” (AACR Special Conference: Hematologic Malignancies: Translating Discoveries to Novel Therapies; 2014, Philadelphia, PA)
Paolo Ghia, Claudia Fazi, Lorenza Pecciarini, Lydia Scarfò, Francesca Cottini, Antonis Dagklis, Agnieszka Janus, Cristina Scielzo, Cinzia Sala, Daniela Toniolo, and Federico Caligaris-Cappio “CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL” (American Society of Hematology meeting, 2010, Orlando)
Francesca Cottini, Teru Hideshima, Chunxiao Xu, Paul G. Richardson, Alec C. Kimmelman, Kwok K. Wong, Federico Caligaris Cappio, Kenneth C. Anderson and Giovanni Tonon “Rescue of YAP1 triggers DNA damage-induced apoptosis in hematological cancers” San Raffaele retreat 28th November 2013, Milan, Italy
Francesca Cottini, Teru Hideshima, Giovanni Tonon and Kenneth C. Anderson “The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma” (American Society of Hematology meeting, 2013, New Orleans)
Division of Molecular Oncology, San Raffaele Scientific Institute, Milan, Italy
Massachusetts General Hospital Cancer Center, Boston
Multiple Myeloma Program, Dana-Farber Cancer Institute, Boston
Get tips from Ohio State experts right to your inbox.
We'll be in touch every so often with health tips, patient stories, important resources and other information you need to keep you and your family healthy. Welcome to our online community here at the Ohio State Wexner Medical Center!